Evidence map›Paper›PMID 39227591›Full record

ArticleLight, science & applications2024

Fiber-optic drug delivery strategy for synergistic cancer photothermal-chemotherapy.

Yongkang Zhang, Jie Zheng, Fangzhou Jin, Jie Xiao, Ni Lan, Zhiyuan Xu, Xu Yue, Zesen Li, Chengzhi Li, Donglin Cao and 4 more

Abstract read
In one paragraph

Article in Light, science & applications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Quantum Photothermal Self-Monitoring Fiber Probes for In Vivo Photothermal Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Ferritin Fused with MiniSOG forACS applied bio materials · 2025
    Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yongkang ZhangGuangdong Provincial Key Laboratory of Optical Fiber Sensing and Communications, Institute of Photonics Technology, Jinan University, Guangzhou, China.
Jie ZhengThe MOE Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou, China.
Fangzhou JinGuangdong Provincial Key Laboratory of Optical Fiber Sensing and Communications, Institute of Photonics Technology, Jinan University, Guangzhou, China.
Jie XiaoThe MOE Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou, China.
Ni LanInstitute of Biomedicine, College of Life Science and Technology, Jinan University, Guangzhou, China.
Zhiyuan XuGuangdong Provincial Key Laboratory of Optical Fiber Sensing and Communications, Institute of Photonics Technology, Jinan University, Guangzhou, China.
Xu YueGuangdong Provincial Key Laboratory of Optical Fiber Sensing and Communications, Institute of Photonics Technology, Jinan University, Guangzhou, China.
Zesen LiGuangdong Provincial Key Laboratory of Optical Fiber Sensing and Communications, Institute of Photonics Technology, Jinan University, Guangzhou, China.
Chengzhi LiDepartment of Interventional Radiology and Vascular Surgery, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China.
Donglin CaoDepartment of Laboratory Medicine, the Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, China.
Yifei WangInstitute of Biomedicine, College of Life Science and Technology, Jinan University, Guangzhou, China.
Wenbin ZhongThe MOE Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou, China.
Yang RanGuangdong Provincial Key Laboratory of Optical Fiber Sensing and Communications, Institute of Photonics Technology, Jinan University, Guangzhou, China. tranyang@jnu.edu.cn.ORCID http://orcid.org/0000-0002-9170-7620
Bai-Ou GuanGuangdong Provincial Key Laboratory of Optical Fiber Sensing and Communications, Institute of Photonics Technology, Jinan University, Guangzhou, China. tguanbo@jnu.edu.cn.ORCID http://orcid.org/0000-0002-3790-2986

Funding

National Natural Science Foundation of China (National Science Foundation of China) 62335010
6 · The paper itself

Abstract

Chemotherapy is one of the conventional treatments for cancer in clinical practice. However, poor delivery efficiency, systemic toxicity, and the lack of pharmacokinetic monitoring during treatment are the critical limitations of current chemotherapy. Herein, we reported a brand-new antitumor drug delivery strategy that harnesses an optical fiber endoscopically therapeutic probe. The fiber probe carries photosensitizers in the fiber core and antitumor agents on the fiber surface mediated by a temperature-responsive hydrogel film, giving rise to an activable photothermal-chemotherapy that orchestrates the localized hyperthermia and thermal-stimuli drug release to the tumor lesion. Furthermore, the dynamical drug release and in-situ temperature can be real-time supervised through the built-in fiber sensors, including the reflective Mach-Zehnder interferometer and fiber Bragg grating, to visualize the therapy process and thus improve the safety of treatment. Compared with conventional methods, the fiber-optic drug delivery can adequately take advantage of the chemotherapeutics through collaboratively recruiting the photoheating-mediated enhanced permeability and the hydrogel particle-assisted high drug retention, shedding new light on a "central-to-peripheral" drug pervasion and retention mechanism to destroy tumors completely. The fiber-optic chemotherapy strategy incorporates precise drug delivery, accurate controllability of drug release, high drug permeability and retention in tumor, low off-target rate, and real-time drug release and temperature feedback, performing a straightforward and precise photothermal-chemotherapy pathway. More than that, the proposed strategy holds tremendous promise to provide a revolutionized on-demand drug delivery platform for the highly efficient evaluation and screening of antitumor pharmaceuticals.

Identifiers

PMID39227591
PMCPMC11372069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.